Patent intelligence · US
US 7504101
Methods for enhancing antigen-specific immune response using antibodies that bind OX-40
Methods for enhancing antigen-specific immune response using antibodies that bind OX-40
Patent details — US 7504101
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 17, 2009
- Expiration
- Mar 12, 2029
- Applicant
- Sisters of Providence in Oregon
- Claims
- 16
- CPC classes
- A61K, A61K2039/55516, A61K38/177, A61K39/0005
Quick answer
US 7504101 (Methods for enhancing antigen-specific immune response using antibodies that bind OX-40) is held by Sisters of Providence in Oregon. Status: granted. Granted Mar 17, 2009. Expires Mar 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sisters of Providence in Oregon
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/55516, A61K38/177, A61K39/0005, A61K39/39, A61P
More from Sisters of Providence in Oregon
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Frequently asked questions
What is US patent 7504101?
US 7504101 (Methods for enhancing antigen-specific immune response using antibodies that bind OX-40) is held by Sisters of Providence in Oregon. Status: granted. Granted Mar 17, 2009. Expires Mar 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7504101?
Sisters of Providence in Oregon is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 7504101 expire?
Our index shows an expiration date of Mar 12, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.